Background: Cross-sectional studies reported a novel set of hydroxylated ultra-long-
Introduction
Colorectal cancer (CRC) accounts for one fourth of all cancer deaths worldwide and is the second leading cause of cancer mortality in the United States and Europe (1, 2) .
Since less than 15 percent of the variation in risk of CRC has been attributed to heritable genetic factors (3, 4) , exposures such as nutrients, microbial metabolites, toxins, and pathogens are likely to play a significant role in CRC development.
Exposures that have been associated with increased risks of CRC include obesity, cigarette smoking, alcohol use, and consumption of n-6 polyunsaturated fatty acids, all of which contribute to oxidative stress and inflammation (reviewed in Stone, et al. (5) ). On the other hand, regular consumption of aspirin -an antioxidant and antiinflammatory drug -reduces CRC risk (5, 6) . Aspirin inhibits both COX-1 and COX-2 enzymes, preventing the production of inflammatory prostaglandins and thromboxanes (7) and also acetylates COX-2 and thereby allows conversion of n-3 and n-6 fatty acids to inflammation-resolving compounds (lipoxins are derived from n-6 fatty acids and resolvins and protectins from n-3 and n-6 fatty acids) (8) . This combination of factors suggests that CRC may result from an imbalance in production and removal of reactive electrophiles and inflammatory products that can initiate and promote tumors (5, 9, 10) .
Recently, Ritchie et al., used untargeted high-resolution mass spectrometry (HRMS) to detect a novel class of polyunsaturated, hydroxylated, ultra-long-chain fatty acids (ULCFAs, containing between 28 and 36 carbons) that was associated with reduced risks of CRC in three case-control studies (11) . Using accurate-mass signatures of a dozen representative ULFCAs, Ritchie et al. reported that concentrations of these molecules were not correlated with either the tumor stage or type of treatment in cases.
Furthermore, ULCFA levels declined with increasing age (whereas risk of CRC increases with age) in cases and controls, indicating a possible protective effect of ULCFAs (12) . Moreover, a large follow-up study of colonoscopy patients by the same authors indicated that subjects under the age of 50 that were in the lowest decile of ULCFA-serum concentrations had a relative CRC risk of 10.1 (C.I.: 6.4 -16.4) (13).
In attempting to elucidate a protective mechanism for these molecules, Ritchie et al.
dosed human CRC (SW620) cells with 28-carbon ULFCAs that had been isolated from human serum, and reported reduced production of pro-inflammatory markers (NFκB, IκBα, and NOS2) (14) . Since, as noted above, inflammation has been a hallmark of CRC (5, 9, 15) , the inverse correlation of ULCFA levels and CRC risk would be consistent with a cancer mechanism that favors a pro-inflammatory environment that increases with age. Furthermore, the purported anti-inflammatory or protective properties of ULCFAs could be similar to those of hydroxylated very-long chain fatty acids that are metabolized into inflammation-resolving compounds (i.e. lipoxins, resolvins, and protectins). These compounds are active in the pM -nM range (10) and have epimeric forms that are triggered by aspirin, which reduces risks of CRC and cancer generally (6, 16) .
Remarkably, the provocative findings of Ritchie et al. (11) (12) (13) (14) 17) implicating low serum levels of ULCFAs as potential causes of CRC have not been explored by other investigators. Since all of the reported associations between circulating levels of ULFCAs and CRC were derived from cross-sectional studies (11) it is particularly important to replicate Ritchie's findings with archived cohort samples that were collected prior to CRC diagnosis. This would reduce the likelihood that lower levels of ULFCAs in CRC cases resulted from tumor-induced dysregulation of homeostatic pathways (reverse causality). The purpose of this study is to test the hypothesis that ULFCAs are potentially protective against CRC with pre-diagnostic serum from 95 incident CRC cases and matched controls from the European Prospective Investigation of Cancer and Nutrition (EPIC). Also, since previous reports had implicated consumption of seafood as being potentially protective of CRC (18, 19) , several fresh seafood samples were tested for the presence of ULCFAs.
Materials and Methods

Experimental Design
We adopted a simple regression model to determine whether ULCFAs represent biomarkers on the causal pathway to CRC or are reactive biomarkers related to progression of the disease. Since the EPIC serum had been obtained between 7 d and 14 y prior to CRC diagnosis, we used the (log-scale) difference in ULFCA concentrations (CRC case minus matched control) as the outcome variable in a linear model to simultaneously investigate effects of case status and time to diagnosis (ttd) on the risk of CRC. (Note that these log-scale case-control differences represent case:control ratios in natural scale). The model is shown as follows: ,
where represents the case-control difference of (log-transformed) ULCFA levels for the case-control pair, is the intercept representing the case-control difference at recruitment, and is the coefficient for (d). Evidence favoring a non-zero intercept ( ) would indicate that a given ULCFA level differed on average between cases and controls. A negative intercept, illustrated with the hypothetical example in Figure 1A , would indicate higher ULCFA levels in controls (i.e. a protective effect) as suggested by Ritchie et al. (11) . Likewise, a significant coefficient for ttd ( ), illustrated in Figure 1B , would indicate that the timing of blood collection relative to diagnosis affected the outcome and, therefore, that any case-control difference in the ULFCA level probably reflects progression of CRC. Thus, the combination of a negative and non-significant would point to a potentially causal biomarker of CRC while a significant would point to a reactive biomarker.
Study Population
EPIC is a large prospective cohort study with approximately 520,000 participants, European countries (20) . All study participants provided written informed consent.
Serum was collected at enrollment and dietary information was obtained with a foodfrequency questionnaire (21, 22) . The serum for this investigation consisted of 190 specimens (95 case-control pairs), collected between 1993 and 1997 from subjects in Turin, Italy. Controls were matched to incident cases by age, study enrollment year and season, and gender. Summary statistics for these subjects are listed in Table 1 including ttd, gender, body mass index (BMI), waist circumference, and self-reported consumption of fish and shellfish. These covariates were selected based on previous evidence that BMI and waist circumference are associated with CRC risk (23, 24) and that diets rich in fish oil have reduced risks of inflammation-related diseases (18, 19) . acetic acid and chloroform were from Fisher Scientific (Santa Clara, CA, USA). All chemicals were of analytical grade and were used without purification.
Sample Processing
Shortly after collection, a 0.5-ml aliquot of each serum sample was placed in a cryostraw, sealed, and stored in liquid nitrogen (-196 The electrospray was operated in negative ionization mode. To monitor system stability, pooled quality control samples were injected every tenth sample. Tandem MS/MS spectra were obtained with the Orbitrap platform.
During processing, approximately one third of the serum samples was observed to have a gelled consistency that apparently resulted from a preservative(s) contained in the cryostraws (25, 26) ; gelled serum from EPIC cryostraws has been observed previously (27) . Pairs with at least one gelled sample were analyzed in a single batch (batch 1, n = 96) on the QTOF platform, and the remaining (non-gelled) pairs were analyzed in two batches on either the QTOF platform (batch 2, n = 36) or the Orbitrap platform (batch 3, n = 58).
Several fresh seafood samples were purchased from a local market in Berkeley, California and tested for the presence of ULCFAs. Four types of seafood were tested: raw white shrimp (Thailand), wild American sea scallops, and farmed American Littleneck clams and live mussels. Samples from these four species (50 l) were extracted for lipids using the Bligh and Dyer chloroform extraction method (28, 29) .
These extracts were analyzed on the Orbitrap platform, with the same method as described above.
Data Processing
Raw data were converted to MZXML format for peak picking using ProteoWizard within the R statistical programming environment (30, 31) . For the data collected on the QTOF, parameters include centwave feature detection, orbiwarp retention time correction, minimum fraction of samples in one group to be a valid group = 0.25, Pvalue thresholds for blank versus QC samples = 0.01, isotopic ppm error = 10, width of overlapping m/z slices (mzwid) = 0.015, bandwidth grouping (bw) = 2, minimum peak width = 2 s, maximum peak width=20 s. Parameters for the Orbitrap platform were the same except for: isotopic ppm error = 2.5, minimum peak width = 2 s, maximum peak width=70 s, bw = 5, prefilter peaks = 3, prefilter intensity = 5000, based on XCMS parameters optimized for Orbitrap instruments (32) . The resulting peak tables of retention times, m/z values, and peak intensities were exported for further processing. Subsequent analyses were also performed with the R platform (version 3.2.1) (33).
Because reference standards for the ULCFAs are not available, mass spectra were interrogated for 13 accurate masses representing ULFCAs with between 28 and 36 carbons that had been reported by Ritchie et al (11, 17) . These ULFCAs are listed in Table 2 along with their masses and elemental formulae. We targeted these 13 ions in our analyses and Table 2 
visually examined and five of the features were excluded because some peaks were not reproducibly detected above noise levels (ULFCAs 518, 574, 576, 578, and 592) ( Table 2 ).
For quantitation of ULCFA levels, we followed the same approach as Ritchie et al. (12) and normalized analyte peak areas by the corresponding peak areas of an internal standard ( 13 C-cholic acid, final concentration = 3.0 g/ml). These normalized ULCFA abundances are designated as 'peak-area ratios' (PARs). Preliminary statistical analyses indicated that use of PARs, rather than simply ULCFA peak areas, reduced nuisance variation from instrumental variability and matrix effects.
Statistical Analysis
Batch adjustment was performed with a linear model of the log-transformed PAR of each analyte, which included dummy variables for batch and gel status as independent variables. Residuals from these linear models were used as dependent variables in subsequent statistical analyses. These residuals represent log-transformed PAR values normalized to a mean of zero. Coefficients of variation (CVs) for the eight ULCFAs with acceptable peak morphology were estimated from the error variances ( ) of logtransformed PARs after batch and gel adjustment as (34) ( Table 2) .
Analyte levels were compared between cases and controls using one-sided paired ttests as well as the linear model (1) for evaluating both case-control differences and effects of ttd (Table 3) . Additional linear models were constructed by adding BMI, waist circumference and self-reported consumption of fish and shellfish to model (1) as covariates (Table 4) . Waist circumference had previously been associated with CRC (23, 24) and consumption of fish and shellfish introduces n-3 fatty acids into the diet that purportedly reduce cancer risks (18, 19) and are metabolized to antiinflammatory lipoxins, resolvins, and protectins (14) . As noted above, some serum samples had a gelled consistency. When gel status was added to linear models, no significant main effect or interaction between case-control status and gel status was detected (results not shown).
Results
Approximately normal distributions of logged ULCFA PARs were verified for all three batches, and Kruskal-Wallis tests detected no significant differences across batches (P-value > 0.33). As indicated in Table 2 , CVs ranged from 9.1 to 27.6% (mean 22%) for the 8 ULCFAs with acceptable peak morphology.
As shown in Table 3 , paired-t tests detected significantly lower PARs in cases compared to controls for four 28-carbon ULCFAs (446, 466, 468, and 494).
Significant case-control differences of PARs were confirmed with a negative intercept from model (1) for the same 28-carbon ULCFAs and a fifth 30-carbon ULCFA (492).
Interestingly, these five ULCFAs also showed statistically significant coefficients for time to diagnosis (ttd). Indeed, as shown in Figure 2 , PAR differences between cases and controls decreased with increasing ttd for all 8 ULCFAs. Since case-control differences in levels of these ULCFAs appear to decline with increasing ttd, we conclude that these molecules are reactive biomarkers of CRC progression rather than biomarkers of protective exposure, as hypothesized by Ritchie, et al. (12) . Table 4 shows results from extensions of model (1) to include BMI, waist circumference, and self-reported consumption of fish and shellfish. Since the matched pairs were also matched on gender, the relationship between ULCFAs and gender was tested with an unpaired t-test and no significant difference was observed. The only significant associations observed between these covariates and case-control differences in PAR values were those for ULCFAs 538 and 594 with increasing BMI. No ULCFA peaks were distinguishable from background noise in the seafood samples.
Although our study confirms that levels of ULCFAs with 28-30 carbons are significantly lower in incident CRC cases than matched controls (11) , the influence of ttd on case-control differences (Figure 2 ) suggests that these fatty acids are more likely to be markers of CRC progression rather than biomarkers of protective exposure. be present in seafood. However, we did not detect ULCFAs in commercial samples of shrimp, scallops, clams or mussels.
While the origin of hydroxylated ULCFAs remains unknown, very long chain (VLC) PUFAs, ranging from 22-34 carbons, have been described (40, 41) and detected in spermatozoa, retinas, and brain tissue (42, 43) . PUFAs longer than 22 carbons are generated by elongase ELOVL-4, which is one of seven endoplasmic-reticulum-bound enzymes responsible for lengthening particular fatty acids (44) . While these VLCPUFAs are not typically hydroxylated, it is plausible that they share common synthetic pathways with the hydroxylated ULCFAs described by Ritchie, et al. Alternatively, elongases ELOVL2 and ELOV5 extend typical-length PUFAs (18-22 carbon) but have not been investigated as possible progenitors of ULCFAs (45).
Our approach for simultaneously comparing paired case-control differences as a function of ttd, embodied in model (1), offers an efficient mechanism for differentiating biomarkers of exposure from those of disease progression and is sufficiently general for use with either targeted or untargeted analyses of biospecimens from prospective cohorts. Previous analyses that employed ttd in studies of disease etiology have been restricted to biomarker levels in cases only (22, 46, 47) and have also been used to exclude cases diagnosed relatively soon after specimen collection (e.g. 2-5 years) (48) (49) (50) .
For the CRC case-control samples evaluated in the current study, the 28-carbon ULCFAs were the class most highly associated with case status and ttd (Table 3) .
Ritchie, et al. reported that several 36-carbon compounds were also highly discriminating between cases and controls for both CRC (11, 13) (17, 51) . However, the only 36-carbon ULCFA that we were able to quantify was 594, which was not significantly associated with either CRC case status or ttd (Table 3) , although the plot in Figure 2 suggests a weak, but consistent, trend with ttd.
Discussion
Although our results tend to downplay the potential roles of ULCFAs as biomarkers of protective exposure, they may be worth evaluating as diagnostic biomarkers of CRC.
Indeed, relationships shown in Table 3 point to significant reductions in three of the 28-carbon ULCFAs (446, 466, & 468) starting between about 1,500 -3,000 d (3 -7 y) prior to diagnosis.
We emphasize that our methods relied on accurate masses to pinpoint ULCFAs and employed quantitation relative to 13 C-cholic acid (internal standard). With availability of reference standards, it would be possible to detect and quantitate these molecules with greater precision and thus to reduce measurement errors and resulting attenuation biases that probably weakened associations observed with CRC status and ttd.
However, improved standardization would be unlikely to remove the consistent effects of ttd that were observed in our samples of CRC cases and controls from the EPIC cohort ( Figure 2 ).
We recognize that our study is small and has limited power to detect associations between ULCFAs and CRC. Nonetheless, these results offer important clues that the ULCFAs might be useful diagnostic markers. Validation with larger sample sets is now necessary. Use of a linear model (model 1) to differentiate a causal biomarker from a disease-related biomarker. Hypothetical data representing levels of a biomarker were generated for case-control pairs, transformed to natural logarithms, normalized to zero mean, and the case-control differences plotted versus time to diagnosis (ttd). (A) Case-control differences are consistently less than zero indicating that biomarker levels are greater in controls than in cases and are not affected by ttd. This would indicate a biomarker of protective effect. (B) Case-control differences diminish with increasing ttd, consistent with a biomarker of disease progression. Linear-model plots. Case-control differences for ULCFA levels versus time to diagnosis (ttd) [model (1)]. Each point represent the difference in log-transformed peak-area ratios (PAR) (ULCFA/ 13 C-cholic acid), normalized to a mean of zero, for a given case-control pair after batch adjustment. Error bands represent 95% confidence intervals.
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